RESERPINE
LOE ApproachingNDAORALTABLET
Approved
Mar 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Reserpine is an oral alkaloid antihypertensive agent approved in 1955 for blood pressure management. It works by depleting catecholamine stores in sympathetic nerve endings, reducing sympathetic outflow and lowering blood pressure. This product represents a historic antihypertensive class now largely superseded by modern agents.
LOE Approaching
Minimal commercial activity expected with approaching loss of exclusivity; support team likely small and stable.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on reserpine offers minimal career advancement opportunities given its legacy status and approaching loss of exclusivity. Roles are primarily compliance and maintenance-focused rather than growth-oriented, suitable for specialists managing mature product portfolios.
Regulatory Affairs SpecialistCompliance Officer
Worked on RESERPINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.